CoChat

Characterization of tau binding by gosuranemab

Open access
Sopko, Richelle, Golonzhka, Olga, Arndt, Joseph, Quan, Chao, Czerkowicz, Julie, Cameron, Andrew, Smith, Benjamin, Murugesan, Yogapriya, Gibbons, Garrett, Kim, Soo-Jung, Trojanowski, John Q., Lee, Virginia M.Y., Brunden, Kurt R., Graham, Danielle L., Weinreb, Paul H., Hering, Heike · 2020 · Neurobiology of Disease
Cited by 63

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Deposition of tau aggregates in the brain is a pathological hallmark of several neurodegenerative diseases, termed tauopathies, such as Alzheimer's disease (AD), corticobasal degeneration, and progressive supranuclear palsy (PSP). As transcellular spread of pathological tau aggregates has been implicated in disease progression, immunotherapy is being considered as a treatment for tauopathies. Here we report a detailed biochemical and biophysical characterization of the tau-binding properties of gosuranemab, a humanized monoclonal antibody directed against N-terminal tau that is currently being investigated as a treatment for AD. Binding experiments showed that gosuranemab exhibited high affinity for tau monomer, tau fibrils, and insoluble tau from different tauopathies. Epitope mapping studies conducted using X-ray crystallography and mutagenesis showed that gosuranemab bound to human tau residues 15-22. Immunodepletion of pathological human brain homogenates and transgenic mouse interstitial fluid (ISF) with gosuranemab resulted in reduced tau aggregation in tau biosensor cells. Preincubation of seed-competent AD-tau with gosuranemab significantly inhibited tau aggregation in mouse primary cortical neurons. Gosuranemab also significantly reduced unbound N-terminal tau in cerebrospinal fluid (CSF) from individuals with PSP and AD, and in ISF and CSF of treated transgenic mice. These results are consistent with the >90% target engagement observed in the CSF of some clinical trial dosing cohorts and support the evaluation of gosuranemab as a potential treatment for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2020.105120

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 63

Metadata

Authors
Sopko, R., Golonzhka, O., Arndt, J., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Murugesan, Y., Gibbons, G., Kim, S.-J., Trojanowski, J. Q., Lee, V. M. Y., Brunden, K. R., Graham, D. L., Weinreb, P. H., & Hering, H.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2020-12
Volume
146
Pages
105120
ISSN
0969-9961 (ISSN-L)
OpenAlex
W3091362147
Cited by
63
References
39
FWCI
4.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of tau binding by gosuranemab. https://app.cochat.ai/papers/10.1016/j.nbd.2020.105120
The paper
Sopko, R., Golonzhka, O., Arndt, J., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Murugesan, Y., Gibbons, G., Kim, S.-J., Trojanowski, J. Q., Lee, V. M. Y., Brunden, K. R., Graham, D. L., Weinreb, P. H., & Hering, H. (2020). Characterization of tau binding by gosuranemab. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2020.105120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.